Xeljanz

Chemical Nametofacitinib
Dosage FormTablets (oral; 5 mg, 10 mg); Extended release tablets (oral; 11 mg)
Drug ClassKinase inhibitors
SystemDigestive
CompanyPfizer Inc.
Approval Year2012

Indication

  • Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
  • Indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
  • Indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xeljanz (tofacitinib) Prescribing Information2012Pfizer Inc., New York, NY
Document TitleYearSource
Comparative efficacy and safety of janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.2021Therapeutic Advances in Musculoskeletal Disease
Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: A systematic review and meta-analysis.2020Mayo Clinic
Risk of venous thromboembolism associated with tofacitinib and baricitinib: A systematic review and indirect meta‐analysis. 2020Pharmacotherapy
Efficacy of tofacitinib in the treatment of psoriatic arthritis: A systematic review. 2020Advances in Therapy
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.2020Cochrane Database of Systematic Reviews
Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.2019Journal of International Medical Research
Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials.2019Therapeutic Advances in Musculoskeletal Disease
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis. 2019Seminars in Arthritis and Rheumatism
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.2019Annals of the Rheumatic Diseases
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. 2019Rheumatology International
The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: A systematic literature review.2018Drug Safety
Systematic review and network meta‑analysis of treatment for moderate‑to‑severe ulcerative colitis. 2018International Journal of Clinical Pharmacy
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. 2017Seminars in Arthritis and Rheumatism
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.2017Cochrane Database of Systematic Reviews
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.2017Cochrane Database of Systematic Reviews
Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: Systematic literature review and network meta-analysis.2017International Journal of Rheumatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.2017Cochrane Database of Systematic Reviews
Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. 2017Journal of the European Academy of Dermatology and Venereology
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. 2017Alimentary Pharmacology and Therapeutics
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.2017Cochrane Database of Systematic Reviews
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a cochrane systematic review and network meta-analysis (NMA).2016Cochrane Database of Systematic Reviews
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.2016Cochrane Database of Systematic Reviews
Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: Results from a network meta-analysis. 2016Clinical Therapeutics
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.2016BMJ
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.2016Rheumatology